Statement re. HSE Prosecution

Novacyt S.A.

21 January 2025

 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Statement re. Health and Safety Executive Prosecution

Paris, France, and Eastleigh and Manchester, UK - 21 January 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that, following an investigation by the Health and Safety Executive ("HSE"), Lab 21 Healthcare Ltd ("Lab 21"), a non-trading subsidiary of Novacyt, has been charged with health and safety offences relating to a facility it previously operated.  

The charges relate to Lab 21's site based at Axminster, Devon and relate to the use of biological agents at the site. The lease for the site was taken over by Lab 21 from Omega Diagnostics Ltd ("Omega"), as part of the acquisition by Lab 21 of Omega's Infectious Diseases business announced on 28 June 2018. The operations that are subject to the charges no longer form any part of the Company's ongoing business.

An initial Magistrates' Court hearing has been set for 18 March 2025.

The Company will make a further announcement following the outcome of the case.

Contacts

Novacyt SA			https://novacyt.com/investors
Lyn Rees, Chief Executive Officer			Via Walbrook PR
Steve Gibson, Chief Financial Officer
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)				[phone]
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Deutsche Numis (Joint Broker)				[phone]
Freddie Barnfield / Duncan Monteith / Michael Palser
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit		[phone] [e-mail] / [e-mail]
Walbrook PR (Financial PR & IR) Paul McManus / Lianne Applegarth Phillip Marriage / Alice Woodings			[phone] or [e-mail] [phone] / [phone]  [phone] / [phone]

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests ·    Precision Medicine: DPYD genotyping assay ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: ·    Ranger® Technology: automated DNA sample preparation and target enrichment technology ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the life sciences industry: ·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry ·    Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

 

END